Kamada Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
23.1%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
$0.49next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 15 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Annual Revenue Annually180.5MTarget: 200000000 to 205000000
Adjusted EBITDA Annually42MTarget: 50000000 to 53000000
Quarterly Revenue Quarterly45.2M
Watch Items
- Middle East Geopolitical ConflictTrigger: Escalation of regional conflicts impacting operations or supply chains in IsraelAction: Assess business continuity plans, evaluate safety of local manufacturing facilities, and monitor international shipping routes.
- San Antonio Plasma Center CommercializationTrigger: Ramp-up of normal source plasma sales following FDA approval in early 2026Action: Track volume of plasma collected and verify progress toward the estimated $8 million to $10 million annual revenue target at full capacity.
- Inhaled Alpha-1 Antitrypsin (AAT) Phase 3 TrialTrigger: Release of clinical data or regulatory milestonesAction: Evaluate potential market expansion into the $2 billion AATD-related lung disease market.
Research as of 19 Jun 2026